Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis Sells 73,434 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 73,434 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the transaction, the chief executive officer now directly owns 641,731 shares of the company’s stock, valued at $27,016,875.10. This trade represents a 10.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ultragenyx Pharmaceutical Trading Down 0.6 %

RARE stock opened at $40.87 on Thursday. The stock has a market cap of $3.78 billion, a PE ratio of -6.45 and a beta of 0.60. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The company has a 50-day moving average price of $42.80 and a 200 day moving average price of $48.94.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on RARE shares. Wells Fargo & Company boosted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Royal Bank of Canada reissued an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group upped their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Finally, Wedbush reissued a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.50.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter worth about $35,000. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth about $42,000. True Wealth Design LLC bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at about $43,000. Finally, Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares during the period. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.